UY37745A - Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias - Google Patents

Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias

Info

Publication number
UY37745A
UY37745A UY0001037745A UY37745A UY37745A UY 37745 A UY37745 A UY 37745A UY 0001037745 A UY0001037745 A UY 0001037745A UY 37745 A UY37745 A UY 37745A UY 37745 A UY37745 A UY 37745A
Authority
UY
Uruguay
Prior art keywords
fusionates
compositions
treatment
bicyclic compounds
parasitary
Prior art date
Application number
UY0001037745A
Other languages
English (en)
Inventor
Suresh Nagle Advait
K Lerario Isabelle
Pearly NG Shuyi
Maxim Ratnikov
Fang Liang
Yongping Xie
Valentina Molteni
m smith Jeffrey
Xiaodong Liu
Jan Jiricek
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY37745A publication Critical patent/UY37745A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable del mismo; un método para fabricar los compuestos de la invención, y sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
UY0001037745A 2017-05-31 2018-05-23 Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias UY37745A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513211P 2017-05-31 2017-05-31
US201762581919P 2017-11-06 2017-11-06

Publications (1)

Publication Number Publication Date
UY37745A true UY37745A (es) 2019-01-02

Family

ID=62749123

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037745A UY37745A (es) 2017-05-31 2018-05-23 Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias

Country Status (26)

Country Link
US (2) US11384078B2 (es)
EP (1) EP3630771B1 (es)
JP (1) JP7187490B2 (es)
KR (1) KR20200010275A (es)
CN (1) CN110678468B (es)
AR (1) AR111826A1 (es)
AU (1) AU2018276190B2 (es)
BR (1) BR112019024804A2 (es)
CA (1) CA3060990A1 (es)
CL (1) CL2019003467A1 (es)
CO (1) CO2019013254A2 (es)
CR (1) CR20190545A (es)
CU (1) CU24543B1 (es)
DO (1) DOP2019000299A (es)
EC (1) ECSP19084722A (es)
ES (1) ES2927207T3 (es)
IL (1) IL270927B (es)
JO (1) JOP20190278A1 (es)
MA (1) MA50495A (es)
MX (1) MX2019014321A (es)
PE (1) PE20201148A1 (es)
PH (1) PH12019502652A1 (es)
RU (1) RU2738647C1 (es)
TW (1) TW201902894A (es)
UY (1) UY37745A (es)
WO (1) WO2018220531A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
CN115397807B (zh) * 2020-04-17 2024-08-13 帝斯曼知识产权资产管理有限公司 用于制备取代的烯胺化合物的方法
US20230250064A1 (en) * 2020-06-23 2023-08-10 Shanghai Meiyue Biotech Development Co., Ltd. Preparation method for fused pyrazole-type compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053275A1 (de) 2000-10-27 2002-05-02 Dresden Arzneimittel Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
TWI325865B (en) 2003-02-27 2010-06-11 Palau Pharma Sa Pyrazolopyridine derivatives
AR085410A1 (es) 2011-02-25 2013-10-02 Dow Agrosciences Llc Derivados de pirazol heteroaril-sustituidos, composiciones pesticidas que los comprenden y su uso en el control de plagas
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013106254A1 (en) * 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
ES2655030T3 (es) 2012-11-19 2018-02-16 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY35400A (es) * 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
WO2014151729A1 (en) * 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
MX368072B (es) * 2013-12-19 2019-09-18 Novartis Ag Derivados de [1,2,4]-triazolo-[1,5-a]-pirimidina como inhibidores del proteasoma de protozoarios para el tratamiento de enfermedades parasitarias tales como leishmaniasis.
EP3227288B1 (de) 2014-12-02 2018-08-29 Bayer CropScience AG Bicyclische verbindungen als schädlingsbekämpfungsmittel
CN107635984B (zh) 2015-03-11 2021-04-13 Fmc公司 杂环取代的二环唑杀有害生物剂
AR104749A1 (es) 2015-05-29 2017-08-09 Glaxosmithkline Ip Dev Ltd Imidazo[1,2-b][1,2,4]triazina sustituida, composición farmacéutica y combinación que lo comprenden, y su uso para la fabricación de un medicamento
ES2856899T3 (es) 2015-08-07 2021-09-28 Glaxosmithkline Ip Dev Ltd Compuestos
CN115054600B (zh) * 2016-05-03 2024-06-14 拜耳制药股份公司 芳族磺酰胺衍生物
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية

Also Published As

Publication number Publication date
ECSP19084722A (es) 2019-12-27
CN110678468B (zh) 2022-07-29
US20200109142A1 (en) 2020-04-09
IL270927B (en) 2022-01-01
CN110678468A (zh) 2020-01-10
MX2019014321A (es) 2020-02-05
DOP2019000299A (es) 2019-12-15
CO2019013254A2 (es) 2020-01-17
JP2020521775A (ja) 2020-07-27
EP3630771B1 (en) 2022-06-29
CA3060990A1 (en) 2018-12-06
CU24543B1 (es) 2021-08-06
RU2738647C1 (ru) 2020-12-15
EP3630771A1 (en) 2020-04-08
IL270927A (en) 2020-01-30
JP7187490B2 (ja) 2022-12-12
AR111826A1 (es) 2019-08-21
US20220324863A1 (en) 2022-10-13
PE20201148A1 (es) 2020-10-26
JOP20190278A1 (ar) 2019-11-28
BR112019024804A2 (pt) 2020-06-09
MA50495A (fr) 2021-04-28
AU2018276190A1 (en) 2019-11-07
ES2927207T3 (es) 2022-11-03
CL2019003467A1 (es) 2020-03-13
PH12019502652A1 (en) 2020-07-13
TW201902894A (zh) 2019-01-16
WO2018220531A1 (en) 2018-12-06
KR20200010275A (ko) 2020-01-30
US11384078B2 (en) 2022-07-12
CU20190095A7 (es) 2020-10-20
AU2018276190B2 (en) 2020-05-14
CR20190545A (es) 2020-01-15

Similar Documents

Publication Publication Date Title
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
ECSP12012171A (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos
DOP2021000077A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CL2020001020A1 (es) Derivados de bencimidazol y sus usos.
UY36124A (es) Derivados de carboxamida
UY36123A (es) Derivados de carboxamida
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
ECSP19019613A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
DOP2020000088A (es) Derivados de piridinona y su uso como inhibidores selectivos de alk–2.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
UY38133A (es) Nuevos inhibidores de cdk8/19
EA201992577A1 (ru) 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
ECSP22030740A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CU20160170A7 (es) Derivados de carboxamida

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231103